EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 3-Nov-2026 10:16 ET (3-Nov-2026 15:16 GMT/UTC)

25-Oct-2026

ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

Researchers at The University of Texas MD Anderson Cancer Center presented new findings at the European Society for Medical Oncology (ESMO) Congress 2026 showcasing emerging strategies to better monitor treatment responses, to prevent cancer development in high-risk individuals and to improve outcomes with targeted therapies. This research spans multiple disease settings, including lung cancer, triple-negative breast cancer, skin cancer and Lynch syndrome.

25-Oct-2026

Omega-3 EPA linked to longer survival after surgery for colorectal cancer liver metastases

European Society for Medical Oncology
Reports and Proceedings

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.

25-Oct-2026

Machine learning could help identify people at higher risk of common cancers using routine health data

European Society for Medical Oncology
Reports and Proceedings

Machine learning models using routinely collected health information, such as blood tests, medical history and lifestyle factors, could help identify people at higher risk of several common cancers, according to an international study reported at the ESMO Congress 2026.

24-Oct-2026

ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

MADRID, OCTOBER 24, 2026 – An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

Meeting: ESMO Congress 2026

24-Oct-2026

Exploring the potential of immunotherapy in early-stage triple-negative breast cancer

Comprehensive Cancer Centre Gustave Roussy
Reports and Proceedings

Dr Joana Ribeiro, medical oncologist in the Drug Development Department at Gustave Roussy, will present the results of the POP-DURVA clinical trial at the ESMO Congress. Conducted within UNLOCK, a flagship programme of the PRISM Institute, the study evaluated the addition of two immunotherapy injections before surgery in women with localised triple-negative breast cancer. With a strong translational research component, the study also investigated immunotherapy's early effects on the tumour and its immune microenvironment, to better understand the mechanisms underlying treatment response.

24-Oct-2026

Personalized cancer vaccine plus immunotherapy reduces melanoma recurrence after surgery

European Society for Medical Oncology
Reports and Proceedings

Adding a personalised mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026. The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with pembrolizumab alone.

24-Oct-2026

Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer

European Society for Medical Oncology
Reports and Proceedings

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.

23-Oct-2026

Standard kidney function tests underestimate chronic kidney disease in people with cancer

American Society of Nephrology
Reports and Proceedings

Investigators have found that filtration markers used to estimate kidney function miss many cases of chronic kidney disease in individuals with cancer.

The findings will be presented at American Society of Nephrology (ASN) Kidney Week 2026 October 22–25.

Meeting: ASN Kidney Week

23-Oct-2026

Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study

Mayo Clinic
Peer-Reviewed Publication

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

Journal: Nature Medicine

23-Oct-2026

Scientists discover how cancers evade chemotherapy by entering 'Zombie-like state'

Trinity College Dublin
Peer-Reviewed Publication

Scientists at Trinity College Dublin have made an important breakthrough in understanding how cancer cells can evade the cell-killing effects of chemotherapy and enter a “zombie-like state," called premature senescence, that can attract the wound healing properties of the immune system. The scientists also found that senescent cells formed in response to chemotherapy are highly dependent on Inhibitor of Apoptosis Proteins (IAPs) for their continued survival. Accordingly, compounds which neutralised IAPs (called IAP antagonists) selectively eliminated senescent cells by reactivating the self-destruct programme within these cells.

Journal: Science Advances
Funder: European Research Council, Research Ireland